The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).
Marek Trneny
No relevant relationships to disclose
Gregor Verhoef
No relevant relationships to disclose
Martin JS Dyer
No relevant relationships to disclose
Dina Ben Yehuda
No relevant relationships to disclose
Caterina Patti
No relevant relationships to disclose
Miguel Canales
No relevant relationships to disclose
Andrés López
No relevant relationships to disclose
Farrukh Awan
Consultant or Advisory Role - Allos Therapeutics
Paul Montgomery
No relevant relationships to disclose
Andrea Janikova
No relevant relationships to disclose
Anna Maria Barbui
No relevant relationships to disclose
Kazimierz Sulek
No relevant relationships to disclose
Maria José Terol
No relevant relationships to disclose
John A. Radford
No relevant relationships to disclose
Laure Siraudin
No relevant relationships to disclose
Laurence Hatteville
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Sandrine Schwab
Employment or Leadership Position - Sanofi
Corina Oprea
Employment or Leadership Position - Sanofi
Alessandro M. Gianni
No relevant relationships to disclose